We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

56 hedge funds and large institutions have $33.6M invested in Traws Pharma in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

460% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 5

392% more capital invested

Capital invested by funds: $6.83M → $33.6M (+$26.8M)

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

70% more funds holding

Funds holding: 33 → 56 (+23)

0.02% more ownership

Funds ownership: 0.02% → 0.04% (+0.02%)

Holders
56
Holders Change
+23
Holders Change %
+69.7%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
15
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$3.72M
2
BlackRock
BlackRock
New York
+$3.62M
3
Millennium Management
Millennium Management
New York
+$2.84M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.29M
5
CH
CVI Holdings
Delaware
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$514K
2
GCP
GSA Capital Partners
United Kingdom
-$106K
3
TRCT
Tower Research Capital (TRC)
New York
-$61.9K
4
BPA
Beacon Pointe Advisors
California
-$38.9K
5
MA
MONECO Advisors
Connecticut
-$30.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$10.5M +$2.29M +6,073 +28%
BlackRock
2
BlackRock
New York
$4.47M +$3.62M +9,595 +411%
Renaissance Technologies
3
Renaissance Technologies
New York
$3.69M +$3.72M +9,859 New
Millennium Management
4
Millennium Management
New York
$2.82M +$2.84M +7,534 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.06M +$783K +2,076 +60%
CH
6
CVI Holdings
Delaware
$1.31M +$1.32M +3,495 New
Principal Financial Group
7
Principal Financial Group
Iowa
$1.26M +$96.6K +256 +8%
IC
8
Ikarian Capital
Texas
$1.14M +$1.15M +3,054 New
VF
9
Virtu Financial
New York
$836K +$354K +939 +73%
Squarepoint
10
Squarepoint
New York
$680K +$439K +1,165 +179%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$665K +$670K +1,775 New
HF
12
HRT Financial
New York
$663K +$617K +1,637 +1,213%
Northern Trust
13
Northern Trust
Illinois
$414K +$143K +378 +52%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$397K +$400K +1,061 New
GPCM
15
Granite Point Capital Management
Massachusetts
$300K +$302K +800 New
BPA
16
Beacon Pointe Advisors
California
$260K -$38.9K -103 -13%
HWA
17
Hillcrest Wealth Advisors
New Jersey
$251K – – –
Qube Research & Technologies (QRT)
18
Qube Research & Technologies (QRT)
United Kingdom
$138K +$139K +368 New
BFM
19
Boothbay Fund Management
New York
$136K +$137K +364 New
Two Sigma Advisers
20
Two Sigma Advisers
New York
$121K +$122K +323 New
Morgan Stanley
21
Morgan Stanley
New York
$117K +$66.4K +176 +130%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$112K +$74.3K +197 +191%
LP
23
LMR Partners
United Kingdom
$110K +$111K +294 New
Charles Schwab
24
Charles Schwab
California
$107K +$107K +284 New
EDRH
25
Edmond de Rothschild Holding
Switzerland
$100K +$101K +267 New
1
2 3

TRAW Hedge Fund Activity: Q1 2021 in Review

56 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2021, worth a combined $33.6M — up 392% from $6.83M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TRAW positions and 5 closed out — a net gain of 23 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $3.72M. The largest seller was Citadel Advisors, cutting an estimated $514K.

  • 56 institutional investors held Traws Pharma (TRAW) as of Q1 2021, up from 33 in Q4 2020.
  • Funds reported $33.6M of Traws Pharma stock for Q1 2021, up 392% quarter-over-quarter.
  • 28 funds opened new Traws Pharma positions in Q1 2021 and 5 closed out, a net change of +23 holders.
  • The largest Traws Pharma buyer in Q1 2021 was Renaissance Technologies, an estimated $3.72M added.
  • The largest Traws Pharma seller in Q1 2021 was Citadel Advisors, an estimated $514K sold.

Based on aggregated 13F filings for Q1 2021.